Figure 4.

ASAS40. Percentage of patients who achieved an ASAS40. P-value of adalimumab treated patients versus placebo is outlined based on an intention-to-treat analysis (χ2-test). One patient in each group discontinued prematurely before week 4. The data were included in a last observation carried forward modus. At week 12, all patients remaining patients switched to open label adalimumab.